Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

HR 4703, S 2467, HR 4991 - Vaccine Shortage preparedness Act of 2008
S 2464, HR 4992, HR 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare Part B
S 2465 - Vaccines for Children Access Act of 2008
HR 2 - Children's Health Insurance Program Reauthorization Act of 2009
S 75 - Generics First Act 2009
S 80 - Importation of Prescription Drugs
S 301 - Physician Payments Sunshine Act of 2009
HR 276 - Proper Disposal of Unused Pharmaceuticals
HR 5839 - Safeguarding America's Pharmaceuticals Act of 2008
S 3408 - Comparative Effectiveness Research Act of 2008
HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program.
HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008
S 2467 - Vaccine shortage preparedness Act of 2008
S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues
HR 970 and S 1378 - Dextromethorphan Distribution Act of 2007
S 103 - Combat Meth Act of 2005
HR 2207 - Agricultural Disaster Assistance and Western States Emergency - Unfinished business Appropriations Act of 2007
HR 1908 and S 1710 Patent Reform Act of 2007
HR 1 - Implementing the 9/11 Commission recommendations Act of 2007
HR 3162 - Children's Health and Medicare Protection Act of 2007
S 1505 - Affordable Biologics for Consumers Act
S 1695 - Biologics Price Competition and Innovation Act of 2007
HR 1956 - Patent Protection and Innovative Biologic Medicines Act of 2007
HR 1038, S623 - Access to Life-Saving Medicine Act
HR 4083 - Non-prescription Drug Modernization Act of 2007
HR 1308 - Legal Immigrant Children's Health Improvement Act of 2007
HR 5629 - Pathway for Biosimilars Act
HR 1427 - To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes
S 726 - A bill to amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes
HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes

Comparative Effectiveness Research
Public Health Service Act
Drug Importation
Gene Therapy
Direct to Consumer Advertising
Drug Safety Legislation
Global Hypertension

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Free Trade Agreements:
- Intellectual Property Provisions in Panama, Columbia, Korea

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), U.S. Agency for International Development (USAID)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

DoD Authorization Language - Section 701 - Dealing with TriCare
HR 3282 - Comprehensive Immunosuppressive drug Coverage for Kidney Transplant Patients Act of 2007
FY 2009 - Labor HHS Appropriations Bill - Pandemic Influenza Funding and Weldon Ammendment on Thimerosal and Vaccines
LHHS Appropriations, Pandemic Influenza Funding
HR 2642, S 3230 - 2008 Supplemental Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
- Transformational Medical Initiative
HR 2638 - Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009
S 3604 - A bill making supplemental appropriations for economic recovery for fiscal year ending 9/30/08 (economic stimulus package)
HR 7110 - Job Creation and Unemployment Relief Act of 2008
HR 1 - American Recovery and Reinvestment Act

FY 2010 Labor HHS Appropriations Bill
FY 2010 DoD Appropriations Bill

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

S 2029 - Physician Payments Sunshine Act of 2007
HR 6111 - Tax Relief and Healthcare Act (Medicare)
Access to Life Saving Medicines Act
Medicare Part B and Part D - Part D: Non-Interference/Part B: Prompt Pay Removal from Average Sales Price Calculation
HR 6331 - Medicare Improvements for Patients and Providers Act of 2008
HR 2184 - Enhanced Health Care Value for all Act of 2007
HR 3023 Drug and Medical Device Company Gift Disclosure Act
HR 3963 Children's Health Insurance Program Reauthorization Act of 2007
S 2041, HR 4854 - False Claims Act of Correction Act of 2007
HR 3610 - Food and Drug Import Safety Act of 2007

Medicare Prescription Drugs and Modernization Act
Immunosuppressant Legislation

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

S 1145 - Patent Reform Act of 2007
HR 1908 - Patent Reform Act of 2007

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization